paroxetine
DrugDeroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
NCT Number: NCT03277339
Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 4
Centre Hospitalier Henri Laborit, Poitiers, France
Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders
Main objective is to quantify the therapeutic benefit of a thermal cure on generalized anxiety disorders and to understand the psycho-biological substrates of this improvement.
Secondary objectives:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
Thermal cure is realized for 3 weeks
Time frame: The evaluation of primary end point is performed between day 1 and day 24
Time frame: The evaluation of primary end point is performed between day 1 and day 24
Time frame: D= Day D1/D24/D56
Time frame: D= Day D24
Time frame: D= Day D24
Time frame: D= Day D24
Time frame: D= Day D1/D24.
Time frame: D= Day D1/D24.
Time frame: D= Day D56
Centre Hospitalier Henri Laborit
Other
Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (Insula-TOP)
Acronym: Insula-TOP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.